PRRG3

Across TCGA pan-cancer cohorts, PRRG3 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated PRRG3 data layer compared with 20 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher PRRG3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRRG3 expression acts as an unfavorable survival marker.

OV, PAAD, and STAD are the cancer types where PRRG3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.291	0.692	.022	36	view →
PAAD	OS	Median	All	0.011	0.641	<.001	24	view →
STAD	OS	Median	All	0.184	0.730	.001	18	view →
BLCA	OS	Median	All	0.210	0.618	.021	12	view →
LUAD	OS	Median	All	0.235	0.788	.005	12	view →
COAD	OS	Median	All	0.001	0.871	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
HNSC	OS	Median	All	0.260	0.661	.035	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
SKCM	DFS	Median	III,IV	0.075	0.655	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

PRRG3–OV (OS)

Open the OV breakdown →